Viridian Therapeutics (VRDN) appears to be ending on a high note in 2024, because it just reported positive results from its phase 3 THRIVE-2 study using its anti-IGF-1R drug veligrotug [VRDN-001] to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback